60 GSK Annual Report 2011 Financial review Financial review continued & risk The total accruals for rebates, discounts, allowances and returns in These meetings, as appropriate, detail the status of significant the US Pharmaceuticals and Vaccines business were as follows: litigation and governmental investigations and review matters such as the number of claims notied to us, information on potential At 31 claims not yet notied, assessment of the validity of claims, At 31 December December 2010 progress made in settling claims, recent settlement levels and 2011 restated potential reimbursement by insurers.
m m Chargebacks 43 50 The meetings also include an assessment of whether or not there is Managed care, Medicare Part D sufficient information available for us to be able to make a reliable and GPO rebates 372 331 estimate of the potential outcomes of the disputes.
Often, external US government and state programmes 578 536 counsel assisting us with various litigation matters and Cash discounts 18 21 investigations will also assist in the brieng of the Board and senior Customer returns 234 254 management.
Following these discussions, for those matters where Other 24 28 it is possible to make a reliable estimate of the amount of a Total 1,269 1,220 provision, if any, that may be required, the level of provision for legal and other disputes is reviewed and adjusted as appropriate.
Information relating to 2010 has been restated following changes to the classication of items included in certain of the above categories.
Financial position and resources The accrual for rebates to US government and state programmes Property, plant and equipment has increased as a result of the US healthcare reform implemented during 2011.
Our business is science-based, technology-intensive and highly regulated by governmental authorities.
We allocate significant A monthly process is operated to monitor inventory levels at financial resources to the renewal and maintenance of its property, wholesalers for any abnormal movements.
This process uses gross plant and equipment to minimise risks of interruption of production sales volumes, prescription volumes based on third party data and to achieve compliance with regulatory standards.
sources and information received from key wholesalers.
The aim of A number of its processes use chemicals and hazardous materials.
this is to maintain inventories at a consistent level from year to year based on the pattern of consumption.
The total cost of our property, plant and equipment at 31 December 2011 was 18,832 million, with a net book value On this basis, US Pharmaceuticals and Vaccines inventory levels at of 8,748 million.
Of this, land and buildings represented wholesalers and in other distribution channels at 31 December 3,817 million, plant and equipment 2,905 million and assets in 2011 were estimated to amount to approximately one month of construction 2,026 million.
In 2011, we invested 1,061 million turnover.
This calculation uses third party information, the accuracy in new and renewal property, plant and equipment.
This is mainly of which cannot be totally veried, but is believed to be sufciently related to a large number of projects for the renewal, improvement reliable for this purpose.
and expansion of facilities at various worldwide sites.
Property is In respect of the accounting policy for Legal and other disputes, the mainly held freehold.
New investment is nanced from our liquid following briey describes the process by which we determine the resources.
At 31 December 2011, we had capital contractual level of provision that is necessary.
commitments for future expenditure of 504 million and operating lease commitments of 354 million.
We believe that our facilities are In accordance with the requirements of IAS 37, Provisions, adequate for our current needs.
contingent liabilities and contingent assets, we provide for anticipated settlement costs where an outow of resources is We observe stringent procedures and use specialist skills to manage considered probable and a reliable estimate may be made of the environmental risks from these activities.
Environmental issues, likely outcome of the dispute and legal and other expenses arising sometimes dating from operations now modied or discontinued, from claims against the Group.
We may become involved in are reported under Environmental sustainability on page 49 and in significant legal proceedings, in respect of which it is not possible to Note 44 to the financial statements, Legal proceedings.
make a reliable estimate of the expected financial effect, if any, that Goodwill could result from ultimate resolution of the proceedings.
In these cases, appropriate disclosure about such cases would be included in Goodwill increased during the year to 3,754 million at the Annual Report, but no provision would be made.
This position 31 December 2011 from 3,606 million.
The increase primarily could change over time and, therefore, there can be no assurance reects the goodwill arising on the acquisition of Maxinutrition that any losses that result from the outcome of any legal proceedings Group Holdings Limited of 114 million, partly offset by a will not exceed by a material amount the amount of the provisions weakening of overseas currencies.
reported in the Groups financial statements.
Other intangible assets Like many pharmaceutical companies, we are faced with various Other intangible assets include the cost of intangibles acquired complex product liability, anti-trust and patent litigation, as well from third parties and computer software.
The net book value of as investigations of its operations conducted by various governmental other intangible assets as at 31 December 2011 was 7,802 million regulatory agencies.
Throughout the year, the General Counsel of 2010 8,532 million.
The decrease in 2011 reected the Group, as head of the Groups legal function, and the Senior Vice amortisation and impairment of existing intangibles partly offset President and Head of Global Litigation for the Group, who is by additions of 363 million through business combinations and responsible for all litigation and government investigations, routinely other additions.
brief the Chief Executive officer, the Chief Financial officer and the Board of Directors on the significant litigation pending against the Group and governmental investigations of the Group.
GSK Annual Report 2011 61 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Financial position Investments We held investments, including associates and joint ventures, 2011 2010 m m with a carrying value at 31 December 2011 of 1,150 million Assets 2010 1,792 million.
The market value at 31 December 2011 Non-current assets was 1,355 million 2010 2,688 million.
The largest of these Property, plant and equipment 8,748 9,045 investments are in an associate: Aspen Pharmacare Holdings Goodwill 3,754 3,606 Limited which had a book value at 31 December 2011 of Other intangible assets 7,802 8,532 393 million 2010 397 million and an investment in Investments in associates and joint ventures 560 1,081 Theravance, Inc. which had a book value at 31 December 2011 of Other investments 590 711 226 million 2010 244 million.
The investments include equity Deferred tax assets 2,849 2,566 stakes in companies where the Group has research collaborations, Derivative financial instruments 85 97 which provide access to biotechnology developments of potential Other non-current assets 525 556 interest and interests in companies that arise from business Total non-current assets 24,913 26,194 divestments.
Current assets Derivative financial instruments: assets Inventories 3,873 3,837 We had both non-current and current derivative financial Current tax recoverable 85 56 instruments held at fair value of 155 million 2010 190 million.
Trade and other receivables 5,576 5,793 The majority of this amount relates to interest rate swaps and Derivative financial instruments 70 93 foreign exchange contracts designated as accounting hedges.
Liquid investments 184 184 Cash and cash equivalents 5,714 6,057 Inventories Assets held for sale 665 16 Inventory of 3,873 million has increased by 36 million during Total current assets 16,167 16,036 the year.
The increase reects higher Vaccine stocks, principally Total assets 41,080 42,230 Cervarix for the national HPV programme in Japan, partly offset by initiatives to reduce manufacturing cycle times and reduce Liabilities stockholding days through more efficient use of inventory Current liabilities throughout the supply chain.
Short-term borrowings 2,698 291 Trade and other payables 7,359 6,888 Trade and other receivables Derivative financial instruments 175 188 Trade and other receivables of 5,576 million have decreased from Current tax payable 1,643 1,047 2010 reecting specic actions taken to reduce overdue and other Short-term provisions 3,135 4,380 receivables as part of our initiative to reduce working capital.
Total current liabilities 15,010 12,794 Derivative financial instruments: liabilities Non-current liabilities Long-term borrowings 12,203 14,809 We held current and non-current derivative financial instruments Deferred tax liabilities 822 707 held at fair value of 177 million 2010 193 million relating Pensions and other post-employment benets 3,091 2,672 primarily to foreign exchange contracts which represent hedges Other provisions 499 904 of inter-company loans, deposits and legal provisions, but are not Derivative financial instruments 2 5 designated as accounting hedges.
Other non-current liabilities 626 594 Trade and other payables Total non-current liabilities 17,243 19,691 Total liabilities 32,253 32,485 Trade and other payables amounting to 7,359 million have Net assets 8,827 9,745 increased from 2010, reecting working capital initiatives to extend supplier terms towards our 60-day term objective.
Equity Share capital 1,387 1,418 Provisions Share premium account 1,673 1,428 We carried deferred tax provisions and other short-term and Retained earnings 3,370 4,779 non-current provisions of 4,456 million at 31 December 2011 Other reserves 1,602 1,262 2010 5,991 million in respect of estimated future liabilities, Shareholders equity 8,032 8,887 of which 2,772 million 2010 4,000 million related to legal Non-controlling interests 795 858 and other disputes.
Provision has been made for legal and other Total equity 8,827 9,745 disputes, indemnified disposal liabilities, employee related liabilities and the costs of restructuring programmes to the extent that at the balance sheet date a legal or constructive obligation existed and could be reliably estimated.
62 GSK Annual Report 2011 Financial review Financial review continued & risk A summary of the movements in equity is set out below.
Pensions and other post-employment benets We account for pension and other post-employment arrangements 2011 2010 in accordance with IAS 19.
The deficits, net of surpluses before m m Total equity at beginning of year 9,745 10,742 allowing for deferred taxation were 1,476 million 2010 Total comprehensive income for the year 4,424 2,086 1,224 million on pension arrangements and 1,595 million Dividends to shareholders 3,406 3,205 2010 1,425 million on unfunded post-employment liabilities.
Shares issued 250 62 The pension liabilities increased following a decrease in asset values Changes in non-controlling interests 18 in the UK, and reductions in the rates used to discount UK pension Forward contract relating to non-controlling liabilities from 5.5% to 4.8% and US pension liabilities from 5.2% interest 29 to 4.4%, partly offset by a lower long term ination rate and the Shares purchased and cancelled or held deficit reduction contributions of 450 million 2010 456 million.
as Treasury shares 2,191 In December 2010, the UK scheme purchased an insurance contract Consideration received for shares transferred that will guarantee payment of specified pensioner liabilities.
This by ESOP Trusts 45 17 contract was valued at 735 million at 31 December 2011.
Shares acquired by ESOP Trusts 36 16 Share-based incentive plans 191 175 Net debt Tax on share-based incentive plans 50 2 2011 2010 Distributions to non-controlling interests 234 118 m m Total equity at end of year 8,827 9,745 Cash, cash equivalents and liquid investments 5,898 6,241 Share purchases Borrowings repayable within one year 2,698 291 Borrowings repayable after one year 12,203 14,809 In 2011, the Employee Share Ownership Plan ESOP Trusts acquired Net debt 9,003 8,859 36 million of shares in GSK plc 2010 16 million.
Shares are held by the Trusts to satisfy future exercises of options and awards Net debt increased by 144 million as free cash ow and asset under the Group share option and award schemes.
A proportion of disposal proceeds largely funded dividends to shareholders and the shares held by the Trusts are in respect of awards where the share repurchases.
rules of the scheme require us to satisfy exercises through market Movements in net debt purchases rather than the issue of new shares.
The shares held by the Trusts are matched to options and awards granted.
2011 2010 m m At 31 December 2011, the ESOP Trusts held 91 million Net debt at beginning of year 8,859 9,444 2010 105 million GSK shares against the future exercise of Decrease in cash and bank overdrafts 94 642 share options and share awards.
The carrying value of 492 million Cash inow from liquid investments 30 91 2010 845 million has been deducted from other reserves.
Net repayment of short-term loans 37 1,290 The market value of these shares was 1,337 million Debt of subsidiary undertakings acquired 10 20 2010 1,308 million.
Exchange movements 10 61 On 3 February 2011, we announced that we would commence a Other movements 37 13 new long-term share buy-back programme.
169.2 million shares Net debt at end of year 9,003 8,859 were repurchased in 2011 at a cost of 2,191 million.
We intend to make further repurchases of Total equity 12 billion during 2012.
The exact amount and timing of future At 31 December 2011, total equity had decreased from purchases, and whether the shares will be held as Treasury 9,745 million at 31 December 2010 to 8,827 million.
The shares or be cancelled, will be determined by the company and decrease arose principally from share repurchases in the year.
is dependent on market conditions and other factors.
At 31 December 2011, we held 501.2 million shares as Treasury shares 2010 474.2 million shares, at a cost of 6,661 million 2010 6,286 million, which has been deducted from retained earnings.
In the period 1 January 2012 to 2 March 2012 8.6 million shares were purchased at a cost of 122.3 million.
Commitments and contingent liabilities Financial commitments are summarised in Note 39 to the financial statements, Commitments.
Other contingent liabilities and obligations in respect of short and long-term debt are set out in Note 31 to the financial statements, Contingent liabilities and Note 32 to the financial statements, Net debt.
GSK Annual Report 2011 63 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Amounts provided for pensions and post-retirement benets are Contingent liabilities set out in Note 28 to the financial statements, Pensions and other The following table sets out contingent liabilities, comprising post-employment benets.
Amounts provided for restructuring discounted bills, performance guarantees, letters of credit and other programmes and legal, environmental and other disputes are set items arising in the normal course of business, and when they are out in Note 29 to the financial statements, Other provisions.
Contractual obligations and commitments Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs m m m m m The following table sets out our contractual obligations and commitments at 31 December 2011 as they fall due for payment.
Guarantees 112 74 1 1 36 Other contingent liabilities 93 7 43 13 30 Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs Total 205 81 44 14 66 m m m m m Loans 14,817 2,665 2,581 1,333 8,238 In the normal course of business, we have provided various Interest on loans 9,491 750 1,194 978 6,569 indemnification guarantees in respect of business disposals Finance lease obligations 95 34 39 14 8 in which legal and other disputes have subsequently arisen.
Finance lease charges 11 3 6 2 A provision is made where an outow of resources is considered Operating lease probable and a reliable estimate can be made of the likely outcome commitments 354 113 111 47 83 of the dispute and this is included in Note 29 to the financial Intangible assets 7,968 467 1,279 1,347 4,875 statements, Other provisions.
Property, plant & equipment 504 405 94 5 We provide for the outcome of tax, legal and other disputes when Purchase of non-controlling an outow of resources is considered probable and a reliable interests 97 15 82 estimate of the outow may be made.
At 31 December 2011, other Investments 64 17 25 20 2 than for those disputes where provision has been made, it was not Purchase commitments 882 179 323 243 137 possible to make a reliable estimate of the potential outow of Pensions 730 365 365 funds that might be required to settle disputes where the possibility Other commitments 190 93 78 19 of there being an outow was more than remote.
Total 35,203 5,106 6,177 4,008 19,912 The ultimate liability for such matters may vary signicantly from Commitments in respect of loans and future interest payable the amounts provided and is dependent upon the outcome of on loans are disclosed before taking into account the effect litigation proceedings and negotiations with the relevant tax of derivatives.
This is discussed further in Risk factors on pages 72 We have entered into a number of research collaborations to to 77 and Notes 14 and 44 to the financial statements, Taxation develop new compounds with other pharmaceutical companies.
The terms of these arrangements can include upfront fees, equity Cash generation and conversion investments, loans and commitments to fund specified levels of research.
In addition, we will often agree to make further payments A summary of the consolidated cash ow is set out below.
if future milestones are achieved.
2011 2010 m m As some of these agreements relate to compounds in the early Net cash inow from operating activities 6,250 6,797 stages of development, milestone payments will continue for a Net cash outow from investing activities 112 1,868 number of years if the compounds move successfully through the Net cash outow from nancing activities 6,232 5,571 development process.
Generally the closer the product is to Decrease in cash and bank overdrafts 94 642 marketing approval the greater the possibility of success.
The amounts shown above within intangible assets represent the Exchange adjustments 108 81 maximum that would be paid if all milestones were achieved, and Cash and bank overdrafts at beginning of year 5,807 6,368 include 6.1 billion which relates to externalised projects in the Cash and bank overdrafts at end of year 5,605 5,807 discovery portfolio.
A number of new commitments were made in 2011 under licensing and other agreements, including Cash and bank overdrafts at end of year comprise: arrangements with Theravance, Inc. and Janssen Biologics BV.
Cash and cash equivalents 5,714 6,057 The commitments for purchase of non-controlling interests and Overdrafts 109 250 investments represent the maximum amounts payable.
5,605 5,807 In 2009, we reached an agreement with the trustees of the UK The net cash inow from operating activities after taxation paid pension schemes to make additional contributions over a five year was 6,250 million, a decrease of 547 million in sterling terms period, to eliminate the pension deficit identied at the compared with 2010.
The table above The net cash outow from investing activities was 112 million, shows this commitment but excludes the normal ongoing annual 1,756 million lower than 2010, which primarily reected the funding requirement of approximately 120 million.
For further proceeds from the disposal of our shareholding in Quest information on pension obligations, see Note 28 to the financial Diagnostics Inc. and lower purchases of intangible assets during statements, Pensions and other post-employment benets.
the year of 405 million 2010 621 million.
64 GSK Annual Report 2011 Financial review Financial review continued & risk Free cash ow Capital expenditure and financial investment Free cash ow is the amount of cash generated by the business Cash payments for tangible and intangible xed assets amounted after meeting its obligations for interest, tax and dividends paid to 1,328 million 2010 1,635 million.
Disposals realised to non-controlling interests, and after capital expenditure on 337 million 2010 218 million.
Cash payments to acquire non-current tangible and intangible assets.
equity investments of 76 million 2010 279 million were made in the year and sales of equity investments realised 68 million 2011 2010 2010 27 million.
Free cash ow m 4,141 4,486 Free cash ow growth % 8 % 15 % Future cash ow We expect that future operating cash ow will be sufficient to fund Free cash ow was adversely impacted by legal settlements of our operating and debt service costs, to satisfy normal levels of 1,466 million 2010 2,047 million.
Free cash ow excluding capital expenditure, to meet obligations under existing licensing legal settlements was 5,607 million in 2011, compared with agreements, to meet the expenditure arising from the major 6,533 million in 2010, the decline reecting lower contributions restructuring programmes the precise timing of which is uncertain from pandemic products, Avandia and Valtrex and a lower outlined in Note 7 to the financial statements, Major restructuring reduction in working capital compared with 2010 partly offset by programmes and to meet other routine outows including tax and lower restructuring payments and lower tax payments.
dividends, subject to the Risk factors discussed on pages 72 to 77.
Our commitment is to use free cash ow to support increasing We may from time to time have additional demands for finance, dividends, undertake share repurchases or, where returns are more such as for acquisitions and share repurchases.
We have access to attractive, reinvest in the business, including bolt-on acquisitions.
other sources of liquidity from short and long-term capital markets We also intend to use the net proceeds from the disposals of our and banks and other financial institutions, in addition to the cash non-core OTC brands to fund increased returns to shareholders.
ow from operations, for such needs.
A reconciliation of net cash inow from operating activities, Working capital which is the closest equivalent IFRS measure, to free cash ow 2011 2010 is shown below.
Working capital percentage of turnover % 21% 23% Reconciliation of free cash ow Working capital conversion cycle days 210 221 2011 2010 Working capital reduced by 477 million in 2011 compared with a m m reduction of 1,297 million in 2010.
The reduction in 2010 was Net cash inow from operating activities 6,250 6,797 boosted by approximately 600 million of cash related to Purchase of property, plant and equipment 923 1,014 pandemic receivables.
Working capital conversion cycle reduced Purchase of intangible assets 405 621 by 11 days as a result of lower receivables and higher payables.
Disposal of property, plant and equipment 100 92 Interest paid 769 775 Payment policies Interest received 97 107 Group companies are responsible for monitoring and managing Dividends received from joint ventures and their working capital.
The terms of sales collections and supplier associated undertakings 25 18 payments reect local commercial practice.
Distributions to non-controlling interests 234 118 Free cash ow 4,141 4,486 In the UK, the company and each of its UK subsidiaries have policies to ensure that suppliers are paid on time.
In particular, Investment appraisal the UK companies seek: We have a formal process for assessing potential investment s TO SETTLE TERMS OF PAYMENT WITH SUPPLIERS WHEN AGREEING THE proposals in order to ensure decisions are aligned with our overall terms of the transaction strategy.
This process includes an analysis of the impact of the project on earnings, its return on invested capital and an s TO ENSURE THAT SUPPLIERS ARE MADE AWARE OF THE AGREED TERMS assessment of the return based on discounted cash ows.
of payment The discount rate used to perform financial analysis is decided s TO ABIDE BY THE TERMS OF PAYMENT internally, to allow determination of the extent to which The policy permits arrangements for accelerated payment to small investments cover our cost of capital.
the discount rate may be adjusted to take into account country or other risk weightings.
Payment performance At 31 December 2011, the average number of days payable outstanding represented by trade payables of the parent company was nil 2010 nil and in respect of the company and its UK subsidiaries in aggregate was 61 days 2010 50 days.
GSK Annual Report 2011 65 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Maturity profile of gross debt m equivalent 3,000 2,500 2,000 1,500 1,000 500 2012 2013 2014 2015 2017 2018 2025 2033 2034 2038 2039 2042 GBP bonds EUR bonds USD bonds Other bank borrowings Leases In 2011, we returned all of our free cash ow and asset disposal Treasury policies proceeds to shareholders through a balance of dividends and GlaxoSmithKline plc reports in Sterling and pays dividends out of share buy-backs.
We paid out 3.4 billion in dividends and Sterling profits.
The role of Corporate Treasury is to manage and completed 2.2 billion of share repurchases as part of our monitor our external and internal funding requirements and long-term programme.
We have also elected to return the net financial risks in support of our strategic objectives.
Treasury proceeds from the sale of our non-core North American OTC activities are governed by policies and procedures approved by brands to shareholders through payment of a supplemental the Board of Directors, most recently on 14 July 2011. dividend.
A Treasury Management Group TMG meeting chaired by our For further details see Note 41 to the financial statements Financial Chief Financial officer, takes place on a monthly basis to review instruments and related disclosures.
Its members receive management information relating to treasury activities.
Liquidity As at 31 December 2011, our cash and liquid investments were Capital management held as follows: Our financial strategy is regularly reviewed by the Board.
We manage the capital structure of the Group through an appropriate 2011 2010 m m mix of debt and equity that delivers the best returns to shareholders Bank balances and deposits 3,875 5,660 whilst maintaining credit ratings that maximise our exibility to US Treasury and Treasury repo access debt capital markets on attractive terms.
only money market funds 1,839 360 The capital structure of the Group consists of net debt of Corporate debt instruments 9 10 9.0 billion see Note 32, Net debt and shareholders equity of Government securities 175 211 8.0 billion see Consolidated statement of changes in equity 5,898 6,241 on page 139.
Total capital, including that provided by noncontrolling interests of 0.8 billion, is 17.8 billion.
Our centrally managed cash reserves amounted to 3.6 billion at 31 December 2011, all available within 3 months.
This excludes We allocate capital where it can deliver the best returns for our 0.5 billion centrally managed cash held by ViiV Healthcare, an shareholders.
Our commitment is to use free cash ow to support 85% owned subsidiary.
As at that date we had short-term dividends, undertake share repurchases or, where returns are more borrowings repayable within one year of 2.7 billion.
We had attractive, invest in bolt-on acquisitions.
Investment opportunities net debt of 9.0 billion at 31 December 2011.
The table below will continue to be assessed against strict financial criteria.
summarises cash and gross debt after the effects of hedging.
With significant levels of patent or trademark protection, our pharmaceutical products compete largely on product efcacy 2011 2010 or differentiation rather than on price.
Selling margins are sufficient m m to cover normal operating costs and our operations continue to Cash and liquid investments 5,898 6,241 be highly cash generative.
Before legal settlements of 1.5 billion, Gross debt xed 13,621 13,741 net cash inow from operating activities was 7.7 billion in 2011. oating 1,279 1,358 Free cash ow was 4.1 billion.
non-interest bearing 1 1 Net debt 9,003 8,859 66 GSK Annual Report 2011 Financial review Financial review continued & risk Our policy is to borrow centrally in order to meet anticipated Interest rate risk management funding requirements.
The cash ow forecast and funding GSKs objective is to reduce our effective net interest cost and to requirements are monitored by the TMG on a monthly basis.
rebalance the mix of debt at xed and oating interest rates over We have a European Medium Term Note programme of 15 billion.
The policy on interest rate risk management limits the amount At 31 December 2011, we had 8.2 billion of notes in issue under of oating interest payments to a prescribed percentage of this programme.
We also have a US shelf registration statement.
At 31 December 2011, we had $10.0 billion 6.5 billion of notes We use a series of interest rate swaps to redenominate one of our in issue under this programme.
bonds into oating interest rates.
The duration of this swap GSKs long-term borrowings mature at dates between 2013 and matches the duration of the principal instrument.
Our long-term debt ratings have remained unchanged since derivative instruments are accounted for as fair value or cash ow February 2008.
Currently GSK is rated A stable outlook by hedges of the relevant assets or liabilities.
Standard and Poors and A1 stable outlook by Moodys Investors Foreign exchange risk management Service Moodys.
Our short-term debt ratings are A-1 and P-1 with Standard and Poors and Moodys respectively.
Foreign currency transaction exposures arising on internal and external trade ows are not hedged.
The exposure of overseas GSK has access to short-term finance under a US$10 billion operating subsidiaries to transaction risk is minimised by matching commercial paper programme and $4.4 billion of committed local currency income with local currency costs.
For this purpose, our facilities.
The facilities were last renewed in October 2011, and were internal trading transactions are matched centrally and we manage increased from $3.9 billion to $4.4 billion at that time.
We consider inter-company payment terms to reduce foreign currency risk.
this level of committed facilities to be adequate given current Exceptional foreign currency cash ows can be hedged selectively liquidity requirements.
For further information on these facilities, under the management of Corporate Treasury and the TMG.
Where please refer to Note 32 to the financial statements, Net debt.
possible, we manage the cash surpluses or borrowing requirements As well as our committed facilities GSK also had substantial cash of subsidiary companies centrally using forward contracts to hedge and cash equivalents and liquid investments, which amounted to future repayments back into the originating currency.
In 2011 we reviewed our cash In order to reduce foreign currency translation exposure, we seek to balances relative to our debt portfolio and the sources of the debt denominate borrowings in the currencies of our principal assets and that we access in order to improve the efficiency of our balance cash ows.
These are primarily denominated in US dollars, Euros sheet.
As a result, we intend to reduce our effective net funding and Sterling.
Certain borrowings can be swapped into other cost by maintaining a lower level of cash and by diversifying our currencies as required.
sources of funding given the current low interest rate environment.
Borrowings denominated in, or swapped into, foreign currencies Treasury operations that match investments in overseas Group assets may be treated as The objective of treasury activity is to manage the post-tax net cost a hedge against the relevant assets.
Forward contracts are also used or income of financial operations to the benefit of earnings.
in major currencies to reduce our exposure to our investment in Corporate Treasury does not operate as a profit centre.
We use a overseas Group assets.
The TMG reviews the ratio of borrowings to variety of financial instruments to finance our operations and assets for major currencies monthly.
derivative financial instruments to manage market risks from Counterparty risk management these operations.
These derivatives, principally comprising forward foreign currency contracts, interest rate and currency swaps, are Our policy on counterparty risk management is to work with a select group of relationship banks.
Global counterparty limits are used to swap borrowings and liquid assets into our required currencies and to manage exposure to funding risks from changes assigned to each of GSKs banking and investment counterparties based on long-term credit ratings from Moodys and Standard in foreign exchange and interest rates.
Corporate Treasurys usage of these limits is We do not hold or issue derivatives for speculative purposes.
Our monitored daily by a Corporate Compliance officer CCO who treasury policies specically prohibit such activity.
All transactions in operates independently of Corporate Treasury.
Any breach of financial instruments are undertaken to manage the risks arising these limits is reported to the CFO immediately.
The CCO also from underlying business activities, not for speculation.
monitors the credit rating of these counterparties and, when changes in ratings occur, noties Corporate Treasury so that changes can be made to investment levels or authority limits as appropriate.
A full counterparty analysis is presented to the TMG annually for approval.
